Wille Finance
Wille Finance is a Swiss-based multi-family office established in 2007, located in Zug. The firm specializes in managing investments across several asset classes, including private equity, real estate, digital media, and listed assets. In private equity, Wille Finance focuses on both early-stage investments, particularly in life sciences and information and communication technology, and late-stage opportunities. Its real estate strategy emphasizes a long-term, value-add approach, targeting key European cities. In digital media, the company invests in firms that integrate media, content, and technology. Additionally, Wille Finance maintains a net-long portfolio within its listed assets strategy, ensuring a diverse and balanced investment approach managed by an experienced executive team.
Top Sectors
https://crunchbase.com/organization/***
https://linkedin.com/company/***
https://signal.nfx.com/firms/***
Past deals in Zurich
SwissComply
Acquisition in 2024
SwissComply AG is a company based in Zürich, Switzerland, that specializes in providing digital wealth management solutions tailored for independent wealth and asset managers, family offices, and banks. Established in 2014, SwissComply offers a modular assistance system designed to address the challenges faced by asset managers today and in the future. Its services encompass compliance and risk management, information technology, and operational support, allowing clients to optimize their processes, enhance competitiveness, reduce costs, and explore new development opportunities. The company aims to deliver a holistic and cost-effective solution that combines specialized know-how and advanced information technology to meet the evolving needs of its clientele.
Araris Biotech
Series A in 2022
Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering chemotherapeutic agents directly to targeted antibodies. This innovative platform allows for the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, enabling the use of readily available antibodies. The site-specific conjugation process facilitates swift manufacturing and reliable quality control, supporting the creation of safe and potent drugs for various diseases. Araris Biotech's technology is protected by two patents, underscoring its commitment to advancing cancer treatment through improved safety and tolerability for patients.
Invasight
Seed Round in 2022
Invasight is a clinical biotech company based in Zurich, Switzerland, founded in 2019. The company specializes in advancing cell invasion research with the aim of accelerating the development of targeted therapies for invasive cancers. By focusing on the proteins involved in cancer cell invasion, Invasight aims to create therapies that minimize the side effects typically associated with conventional cancer treatments. This innovative approach seeks to provide cancer patients with effective and safe treatment options tailored to their specific needs.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.